Nikulski Financial Inc. bought a new position in Teladoc Health Inc (NYSE:TDOC) in the third quarter, according to its most recent disclosure with the SEC. The firm bought 11,436 shares of the health services provider’s stock, valued at approximately $793,000.
Several other institutional investors and hedge funds also recently modified their holdings of TDOC. Bank of America Corp DE increased its stake in shares of Teladoc Health by 82.8% in the 2nd quarter. Bank of America Corp DE now owns 1,883,185 shares of the health services provider’s stock worth $109,318,000 after acquiring an additional 853,076 shares during the last quarter. Summit Partners L P acquired a new stake in shares of Teladoc Health during the 2nd quarter worth about $37,772,000. Westwood Management Corp IL increased its position in shares of Teladoc Health by 1,342.6% during the 2nd quarter. Westwood Management Corp IL now owns 585,700 shares of the health services provider’s stock worth $34,000,000 after purchasing an additional 545,100 shares during the last quarter. BlackRock Inc. increased its position in shares of Teladoc Health by 9.0% during the 2nd quarter. BlackRock Inc. now owns 5,318,850 shares of the health services provider’s stock worth $308,759,000 after purchasing an additional 437,136 shares during the last quarter. Finally, OppenheimerFunds Inc. acquired a new stake in shares of Teladoc Health during the 2nd quarter worth about $20,163,000.
NYSE TDOC opened at $63.34 on Tuesday. The stock has a market capitalization of $5.04 billion, a price-to-earnings ratio of -38.39 and a beta of 0.96. The company has a debt-to-equity ratio of 0.40, a current ratio of 8.99 and a quick ratio of 8.99. Teladoc Health Inc has a 1-year low of $27.30 and a 1-year high of $89.05.
Teladoc Health (NYSE:TDOC) last released its earnings results on Thursday, November 1st. The health services provider reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.02. The company had revenue of $111.00 million during the quarter, compared to the consensus estimate of $109.94 million. Teladoc Health had a negative return on equity of 14.05% and a negative net margin of 31.32%. Teladoc Health’s revenue was up 61.6% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.55) EPS. On average, sell-side analysts forecast that Teladoc Health Inc will post -1.49 earnings per share for the current fiscal year.
TDOC has been the subject of a number of recent analyst reports. Citigroup reissued a “buy” rating and set a $95.00 price objective on shares of Teladoc Health in a research report on Friday, September 28th. SunTrust Banks raised their price objective on Teladoc Health to $100.00 and gave the stock a “buy” rating in a research report on Monday, September 24th. KeyCorp raised their price objective on Teladoc Health from $90.00 to $94.00 and gave the stock an “overweight” rating in a research report on Friday, September 28th. Oppenheimer raised their price objective on Teladoc Health from $68.00 to $89.00 and gave the stock an “outperform” rating in a research report on Friday, September 28th. Finally, Piper Jaffray Companies raised their price objective on Teladoc Health to $84.00 and gave the stock an “overweight” rating in a research report on Friday, September 21st. One analyst has rated the stock with a sell rating, four have assigned a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $82.95.
In other news, CEO Jason N. Gorevic sold 25,000 shares of Teladoc Health stock in a transaction dated Thursday, August 16th. The stock was sold at an average price of $71.66, for a total value of $1,791,500.00. Following the completion of the transaction, the chief executive officer now owns 561,184 shares in the company, valued at approximately $40,214,445.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Mark Hirschhorn sold 35,000 shares of Teladoc Health stock in a transaction dated Tuesday, September 25th. The shares were sold at an average price of $80.42, for a total value of $2,814,700.00. Following the completion of the transaction, the vice president now owns 10,000 shares of the company’s stock, valued at approximately $804,200. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 166,706 shares of company stock valued at $12,412,229. 3.95% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION WARNING: This report was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/11/06/nikulski-financial-inc-takes-position-in-teladoc-health-inc-tdoc.html.
About Teladoc Health
Teladoc Health, Inc provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.
Further Reading: Diversification For Individual Investors
Want to see what other hedge funds are holding TDOC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teladoc Health Inc (NYSE:TDOC).
Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.